Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human study of BNZ-1 in healthy volunteers
NCT03046459Phase 1Completed
- Sponsor
- Bioniz Therapeutics, Inc.
- Start
- Nov 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules, PEGylated Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BNZ-1 in T-cell large granular lymphocytic leukemia (T-LGLL), cutaneous T-cell lymphoma (CTCL) and alopecia areata, sponsored by Bioniz Therapeutics, Inc. Primary endpoint: Proportion of subjects with related, treatment-emergent adverse events at 30 days. Started Nov 2016; status: completed.
02
Drugs
BNZ-1
03
Conditions
T-cell large granular lymphocytic leukemia (T-LGLL)cutaneous T-cell lymphoma (CTCL)alopecia areata
Beyond the preview
Go deeper on NCT03046459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03046459.